Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cash & Current Investments: 2020-2025

Historic Cash & Current Investments for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $19.4 million.

  • Insight Molecular Diagnostics' Cash & Current Investments rose 471.44% to $19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.4 million, marking a year-over-year increase of 200.71%. This contributed to the annual value of $8.6 million for FY2024, which is 8.44% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Cash & Current Investments of $19.4 million as of Q3 2025, which was down 20.05% from $24.3 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' Cash & Current Investments' 5-year high stood at $59.8 million during Q1 2021, with a 5-year trough of $3.4 million in Q3 2024.
  • Over the past 3 years, Insight Molecular Diagnostics' median Cash & Current Investments value was $11.8 million (recorded in 2023), while the average stood at $14.3 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first crashed by 76.13% in 2024, then spiked by 471.44% in 2025.
  • Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Cash & Current Investments stood at $33.9 million in 2021, then crashed by 39.66% to $20.4 million in 2022, then tumbled by 53.82% to $9.4 million in 2023, then decreased by 8.44% to $8.6 million in 2024, then spiked by 471.44% to $19.4 million in 2025.
  • Its last three reported values are $19.4 million in Q3 2025, $24.3 million for Q2 2025, and $31.0 million during Q1 2025.